Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.

N Engl J Med. 2001 Sep 20;345(12):870-8.

2.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
3.

Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Croom KF, Curran MP, Goa KL, Perry CM.

Drugs. 2004;64(9):999-1028. Review.

PMID:
15101793
4.

The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.

Zanella MT, Ribeiro AB.

Clin Ther. 2002 Jul;24(7):1019-34. Review.

PMID:
12182249
5.

Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

Palmer AJ, Valentine WJ, Ray JA.

Int J Clin Pract. 2007 Oct;61(10):1626-33. Review.

PMID:
17877649
6.

Renoprotection and renin-angiotensin system blockade in diabetes mellitus.

Ruilope LM.

Am J Hypertens. 1997 Dec;10(12 Pt 2):325S-331S. Review.

PMID:
9438777
7.
8.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

9.

Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.

Ravera M, Ratto E, Vettoretti S, Parodi D, Deferrari G.

J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S48-52. Review.

10.

Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Croom KF, Plosker GL.

Drugs. 2008;68(11):1543-69. Review.

PMID:
18627212
11.
12.

Irbesartan and hydrochlorothiazide association in the treatment of hypertension.

Derosa G, Ferrari I, Cicero AF.

Curr Vasc Pharmacol. 2009 Apr;7(2):120-36. Review.

PMID:
19355995
13.

Hypertension and diabetes: the scope of the problem.

Parving HH.

Blood Press Suppl. 2001;2:25-31. Review.

PMID:
11465914
14.

The value of irbesartan in the management of hypertension.

Bramlage P, Durand-Zaleski I, Desai N, Pirk O, Hacker C.

Expert Opin Pharmacother. 2009 Aug;10(11):1817-31. doi: 10.1517/14656560903103820. Review.

PMID:
19601700
15.

AT1-receptor antagonism in hypertension: what has been learned with irbesartan?

Waeber B, Burnier M.

Expert Rev Cardiovasc Ther. 2003 May;1(1):23-33. Review.

PMID:
15030294
16.

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.

Gialama F, Maniadakis N.

Vasc Health Risk Manag. 2013;9:575-92. doi: 10.2147/VHRM.S50831. Epub 2013 Oct 7. Review.

17.

[Irbesartan in clinical practice].

MalishevskiÄ­ MV.

Kardiologiia. 2012;52(11):66-74. Review. Russian.

PMID:
23237398
18.

The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review.

Borghi C, Cicero AF.

High Blood Press Cardiovasc Prev. 2012 Mar 1;19(1):19-31. doi: 10.2165/11632100-000000000-00000. Review.

PMID:
22670584
19.

[Evidence based treatment of diabetic nephropathy].

Sugimoto T.

Nihon Rinsho. 2002 Oct;60 Suppl 10:294-300. Review. Japanese. No abstract available.

PMID:
12430244
20.

[Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].

Shionoiri H, Yasuda G, Takizawa T, Shionoiri F.

Nihon Rinsho. 2005 Jun;63 Suppl 6:394-9. Review. Japanese. No abstract available.

PMID:
15999741
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk